BioMarin Pharmaceuticals BMRN Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's net change in cash?
- BioMarin Pharmaceuticals (BMRN) reported net change in cash of $1.76B in Q1 2026.
- How has BioMarin Pharmaceuticals's net change in cash changed year-over-year?
- BioMarin Pharmaceuticals's net change in cash increased by 1561.7% year-over-year, from $105.96M to $1.76B.
- What is the long-term trend for BioMarin Pharmaceuticals's net change in cash?
- Over 2 years (2021 to 2025), BioMarin Pharmaceuticals's net change in cash has grown at a 144.1% compound annual growth rate (CAGR), from -$61.88M to $368.84M.
- What does net change in cash mean?
- The total change in the company's liquid cash position over the period.
- How do you interpret net change in cash?
- A positive value indicates cash accumulation, while a negative value indicates cash depletion.
- How does net change in cash compare across companies?
- Standard metric across all industries; reflects the overall health and cash-generating capability of the business.